217
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Pediatric Chondromyxoid Fibroma-Like Osteosarcoma

, , , , &
Pages 154-161 | Received 19 Jan 2016, Accepted 31 Oct 2016, Published online: 09 Dec 2016

References

  • Mirra J, Picci P, Gold R, eds. Bone Tumors: Clinical, Radiologic, and Pathologic Correlations. 1st ed. Philadelphia: Lea & Febiger; 1989.
  • Chow L, Lin J, Yip K, et al. Chondromyxoid fibroma‐like osteosarcoma: a distinct variant of low‐grade osteosarcoma. Histopathology 1996;29(5):429–36.
  • Pawel BR. Evening Specialty Conference—Pediatric Pathology Chondromyxoid fibroma-like osteosarcoma. Paper presented at United States and Canadian Academy of Pathology Annual (USCAP) Meeting, Boston, MA. 2015, March.
  • Inwards CY, Squire JA. Low-grade central osteosarcoma. In: WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Fletcher CD, ed.. Lyon, France: IARC press; 2013. pp. 281–8.
  • Kurt A, Unni KK, McLeod RA, Pritchard DJ. Low‐grade intraosseous osteosarcoma. Cancer 1990;65(6):1418–28.
  • Unni KK, Inwards CY, Bridge J, et al. Tumors of the bones and joints. Armed Forces Institute of Pathology; 2005 Series 4, Vol. 2, p. 135-162.
  • Inwards CY, Unni KK. Classification and grading of bone sarcomas. Hematol Oncol Clin North Am. 1995;9(3):545–69.
  • Raubenheimer EJ, Noffke CE. Low-grade intraosseous osteosarcoma of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 1998;86(1):82–5.
  • Malhas A, Sumathi V, James S, et al. Low-grade central osteosarcoma: a difficult condition to diagnose. Sarcoma 2012;2012. PMID: 22851905.
  • Sinha R, Chowdhury SR, Chattopadhyay P, Rajkumar K. Low-grade osteosarcoma of the mandible. J Maxillofacial Oral Surg 2010;9(2):186–90.
  • Foster DA, Yellen P, Xu L, Saqcena M. Regulation of g1 cell cycle progression distinguishing the restriction point from a nutrient-sensing cell growth checkpoint (s). Genes Cance 2010;1(11):1124–31.
  • Melo AN, Eischen CM. Protecting the genome from mdm2 and mdmx. Genes Cancer 2012;3(3-4):283–90.
  • Dujardin F, Binh MBN, Bouvier C, et al. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol, 2011;24(5):624–37.
  • Yoshida A, Ushiku T, Motoi T, et al. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype. Am J Surg Pathol 2012;36(3):423–31.
  • Martin JW, Chilton-MacNeill S, Koti M, et al. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma. PLoS ONE.2014;9(5):e95843.
  • Jeon D, Koh JS, Cho WH, et al. Clinical outcome of low-grade central osteosarcoma and role of CDK4 and MDM2 immunohistochemistry as a diagnostic adjunct. J Orthopaedic Sci 2015;20(3):529–37.
  • Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005;18(1):68–74.
  • Haydon RC, Deyrup A, Ishikawa A, et al. Cytoplasmic and/or nuclear accumulation of the β‐catenin protein is a frequent event in human osteosarcoma. Int J Cancer 2002;102(4):338–42.
  • Clevers H. Wnt/β-catenin signaling in development and disease. Cell, 2006;127(3):469–80.
  • Picci P, Sangiorgi L, Rougraff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J ClinOncol 1994;12(12):2699–705.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.